¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"costs and cost analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • antigen analysis
    Ç׿øºÐ¼®
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • law of weights and measures
    °è·®¹ý
  • trial-and-error learning
    ½ÃÇàÂø¿ÀÇнÀ
  • to and fro motion
    ¿Õº¹¿îµ¿
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • positive and negative syndrome
    ¾ç¼ºÀ½¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gas analysis
    °¡½ººÐ¼®
  • gasometric analysis
    ±âüÁ¤·®ºÐ¼®.
  • gastric analysis
    À§¾×°Ë»ç(¡­ËþÞÛ).
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
  • gravimetric analysis
    Áß·®ºÐ¼®(ñìÕáÝÂà°).
  • gravimetric analysis
    Áß·®ºÐ¼®
  • image analysis
    ¿µ»ó ºÐ¼®
  • immunochemical analysis
    ¸é¿ªÈ­ÇÐÀû ºÐ¼®
  • immunofixation analysis
    ¸é¿ª°íÁ¤ºÐ¼®
  • immunoglobulin subgroup analysis
    ¸é¿ª±Û·ÎºÒ¸°¾ÆÇüºÐ¼®
  • indirect analysis
    °£Á¢ºÐ¼®.
  • infrared spectroscopic analysis
    Àû¿Ü¼± ºÐ±¤ ºÐ¼®
  • inorganic analysis
    ¹«±âºÐ¼®(¡­ÝÂà°).
  • plasma analysis
    Ç÷ÀåºÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • atomic absorption analysis
    ¿øÀÚÈí±¤ºÐ¼®.
  • binding displacement analysis
    °áÇÕº¯À§ºÐ¼®(Ì¿ùêܨêÈÝÂà°).
  • blood gas analysis
    Ç÷¾×°¡½ººÐ¼®.
  • case analysis
    Áõ·ÊºÐ¼® (¡­ºÐ¼®).
  • case analysis
    Áõ·ÊºÐ¼® (¡­ÝÂà°).
  • character analysis
    ¼º°ÝºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®, ¹«¸®ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±ººÐ¼®(¡­ÝÂà°).
  • colo(u)rimetric analysis
    ºñ»öºÐ¼®¹ý(ÝïßäÝÂà°Ûö).
  • combustion analysis
    ¿¬¼ÒºÐ¼®(¡­ÝÂà°).
  • computer-assisted semen analysis (CASA )
    ÄÄÇ»ÅÍ º¸Á¶ Á¤¾×ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • configurational analysis
    ¹èÄ¡ºÐ¼®(ÛÕöÇÝÂà°)
  • decision analysis
    °áÁ¤<°á´Ü>ºÐ¼®
  • displacement analysis
    ÀüÀ§ºÐ¼®
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • amino acid analysis
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®(ÝÂà°)
  • analysis of variance
    ºÐ»êºÐ¼®(ÝÂߤÝÂà°)
  • conformational analysis
    ÀÔüÇüÅ ºÐ¼®(Ø¡ô÷û¡÷¾ÝÂà°)
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • covalent structure analysis
    °øÀ¯°áÇÕ ±¸Á¶ºÐ¼®(ÍìêóÌ¿ùêϰðãÝÂà°)
  • differential thermal analysis
    Â÷ ¿­ºÐ¼®(ó¬æðÝÂà°)
  • displacement analysis
    ´ëÄ¡ºÐ¼®(ÓÛöÇÝÂà°)
  • double isotope dilution analysis
    ÀÌÁß µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ì£ñìÔÒêÈêªáÈýüà·ÝÂà°)
  • elementary analysis
    ¿ø¼Ò ºÐ¼® (êªáÈÝÂà°)
  • elution analysis
    ¿ë¸® ºÐ¼® (éÁ×îÝÂà°)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fluctuation analysis
    ¿äµ¿ ºÐ¼®(èôÔÑÝÂà°)
  • gravimetric analysis
    ¹«°Ô ºÐ¼®(ÝÂà°)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • ionic mobility analysis
    À̿ À̵¿µµ(ì¹ÔÑÓø) ºÐ¼®(ÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • computerized image analysis
    ÄÄÇ»ÅÍ¿µ»óºÐ¼®
  • image analysis
    ¿µ»óºÐ¼®
  • in vitro analysis
    °ü³»ºÐ¼®
  • in vivo analysis
    »ýü³»ºÐ¼®
  • infrared spectroscopic analysis
    Àû¿Ü¼±ºÐ±¤ºÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiometric analysis
    ¹æ»ç¼±ºÐ¼®
  • sequential analysis
    ¼øÂ÷ÀûºÐ¼®
  • spectral analysis
    ½ºÆåÆ®·³ºÐ¼®
  • statistical analysis
    Åë°èÀûºÐ¼®
  • urine analysis
    ¿ä°Ë»ç
  • vector analysis
    ¹éÅͺм®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CEA carcinoembryonic antigen; carotid endarterectomy; cholesterol-esterifying activity; cost-effectivene...
COO chief operating officer; cost of ownership [analysis]
CUA cost-utility analysis [ratio]
LCC lactose coliform count; left circumflex coronary (artery); left common carotid; left coronary cusp; ...
MEDPAR Medical Provider Analysis and Review; Medicare Provider Analysis and Review
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AHCCCS Arizona Health Care Cost Containment System
CE Cost-effectiveness
CEAs Cost-effectiveness analyses
CER Cost-effectiveness ratio
PCI Physiological Cost Index
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electron microprobe analysis
    ÀüÀÚ ¹Ì¼¼ Žħ
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
  • frequency analysis
    ÁÖÆÄ ¼ö ºÐ¼®
  • in vivo analysis
    »ýü³» ºÐ¼®
  • infrared spectroscopic analysis
    Àû¿Ü¼± ºÐ±¤ ºÐ¼®
  • inorganic analysis
    ¹«±â ºÐ¼®
  • laboratory analysis
    ½ÇÇè½Ç ºÐ¼®
  • mixed dentition analysis
    È¥ÇÕ Ä¡¿­±âÀÇ ¾Ç±Ã °ø°£ ºÐ¼®
    È¥ÇÕ Ä¡¿­±â ±³ÇÕÀº ¿µ±¸ Á¦1 ´ë±¸Ä¡°¡ ¸ÍÃâÇÏ´Â 6-7¼¼ºÎÅÍ Çü¼ºµÈ´Ù. ½ÃÁø ¹× ±¸°­ ¹æ»ç¼±ÇÐÀû °Ë»çÀÇ È°¿ëÀ» ÅëÇØ ¿µ±¸Ä¡ ¸ÍÃâ ¼ø¼­¸¦ »ìÆìº¸´Â °ÍÀº Á¤»ó ±³ÇÕ Çü¼ºÀÇ °¡´É¼º ÆÇ´Ü¿¡ À¯È¿ÇÑ Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù.
  • occlusal analysis
    ±³ÇÕ ºÐ¼®
    ±³Çձ⿡ ÀåÂøµÈ ¸ðÇüÀÇ ±³ÇÕ °ü°è¸¦ Æò°¡ÇÏ´Â ±³ÇÕ.
  • qualitative analysis
    Á¤¼º ºÐ¼®
    È­ÇÐ ºÐ¼®¹ý Áß¿¡¼­ ½Ã·á°¡ ¾î¶² ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´ÂÁö ¾Ë¾Æ³»±â À§ÇÑ ºÐ¼®¹ýÀÇ ÃÑĪ. ÀϹÝÀûÀ¸·Î Á¤·® ºÐ¼®À» Çϱâ Àü¿¡ Á¤¼º ºÐ¼®À» ÇÏ°Ô µÈ´Ù. ¹°ÁúÀ» ±¸¼ºÇϰí ÀÖ´Â È­ÇÐÁ¾
  • script analysis
    °¢º» ºÐ¼®
    »çȸ¿¡ Âü¿©ÇÒ ¶§ Çൿ ¾ç»óÀÇ Æ²ÀÎ °¢º»ÀÌ ¸¸µé¾îÁö´Â °úÁ¤¿¡ ´ëÇÑ ºÐ¼®.
  • sequential analysis
    ¼øÂ÷Àû ºÐ¼®
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • space analysis
    °ø°£ ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cost sharing Provisions of an insurance policy that require the insured to pay some portion of covered expenses. Several forms of sharing are in use, e.g., deductibles, coinsurance, and copayments. Cost sharing does not refer to or include amounts paid in premiums for the coverage.
(12 Dec 1998)
sunk cost A cost already incurred and therefore not considered in making a current investment decision.
(05 Dec 1998)
overnight capital cost The capital cost of a project if it could be constructed overnight. This cost does not include the interest cost of funds used during construction.
(05 Dec 1998)
technology, high-cost Advanced technology that is costly, requires highly skilled personnel, and is unique in its particular application. Includes innovative, specialised medical/surgical procedures as well as advanced diagnostic and therapeutic equipment.
(12 Dec 1998)
least cost planning (integrated resource planning) A method of power planning that recognises load uncertainty, embodies an emphasis on risk management, and reviews all available and reliable resources to meet future loads. It takes into consideration all costs of a resource, including capital, labour, fuel, maintenance, decommissioning, known environmental impacts, and the difficulty in quantifying the consequences of selecting one resource over another. Least cost planning seeks to minimise total energy costs.
(05 Dec 1998)
levelised life-cycle cost The present value of the cost of a resource, including capital, financing and operating costs, expressed as a stream of equal annual payments. This stream of payments can be converted to a unit cost of energy by dividing the annual payment amount by the annual kilowatt-hours produced or saved. By levelizing costs, resources with different lifetimes and generating capabilities can be compared.
(05 Dec 1998)
accumulation analysis A technique in which an intermediate of a metabolic pathway accumulates due to selective inhibition of a particular step in that pathway or in a mutant that is deficient in a certain step. The intermediate is then isolated, analyzed, and identified.
(05 Mar 2000)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
actuarial analysis The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
(12 Dec 1998)
amino acid analysis Determination and identification of amino acid content of a macromolecule, identification of a specific amino acid in macromolecules, often a mutated protein, identification and quantitation of amino acid content in blood plasma or urine; a key diagnostic aid.
(05 Mar 2000)
analysis <technique> The separation into component parts or elements, the act of determining the component parts of a substance.
Origin: Gr. Lysis = dissolution
(18 Nov 1997)
analysis of variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
(12 Dec 1998)
base sequence analysis <molecular biology> A method, sometimes automated, for determining the base sequence.
(09 Oct 1997)
bite analysis A study of the relations of the occlusal surfaces of opposing teeth and their effect upon related structures.
Synonym: bite analysis.
(05 Mar 2000)
blood gas analysis <investigation> A test which analyses arterial blood for oxygen, carbon dioxide and bicarbonate content in addition to blood pH. Used to test the effectiveness of respiration.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • market analysis
    ½ÃÀå ºÐ¼®
  • network analysis
    (¼ö)ȸ·Î(¸Á) ÇØ¼®;³×Æ®¿öÅ©ºÐ¼®;(ȸ·Î¸Á ÇØ¼® ¼ö¹ýÀ» ÀÌ¿ëÇÏ¿© ÇÁ·ÎÁ§Æ®ÀÇ °èȹ °ü¸®¸¦ÇÔ
  • neutron activation analysis
    Áß¼ºÀÚ(À¯µµ)¹æ»çÈ­ ºÐ¼®
  • nonstandard analysis
    ÃÊÁØÇؼ®
  • philosphical analysis
    öÇÐÀû ºÐ¼®
  • pollen analysis
    ²É°¡·ç ºÐ¼®;È­ºÐÇÐ
  • qualitative analysis
    Á¤¼º ºÐ¼®
  • quantitative analysis
    Á¤·® ºÐ¼®
  • systems analysis
    (´É·ü,Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ) ½Ã½ºÅÛ ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • cost
    ¿äÇÏ´Ù,ºñ¿ë,°ª
  • cost
    (Á¦ÀÛ.°ø»çµîÀÇ)¿ø°¡;ºñ¿ë;°æºñ;(»óǰ.¼­ºñ½º¿¡´ëÇÑ)´ë°¡;°ª;°¡°Ý;(Àθí.½Ã°£.³ë·ÂµîÀÇ)Èñ»ý;¼Õ½Ç;°íÅë;¼Ò¼Ûºñ¿ë;(ºñ¿ë.´ë°¡°¡ ¾ó¸¶)µé´Ù;(...¿¡°Ô ¾ó¸¶¸¦)µé°Ô(Ä¡¸£°Ô)ÇÏ´Ù;(½Ã°£.³ë·ÂµîÀ»)¿äÇÏ´Ù;(±ÍÁßÇÑ °ÍÀ»)Èñ»ýÇϰÔÇÏ´Ù;ÀÒ°ÔÇÏ´Ù;(¾î¶² °íÅëÀ»)ÁÖ´Ù;ºñ¿ëÀÌ µé´Ù;¿ø°¡¸¦
  • cost accountant
    ¿ø°¡ °è»ê ´ã´çÀÚ
  • cost accounting
    ¿ø°¡ °è»ê
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á